-
-
Reuters (September 22, 2023) Insight: Big Pharma bets on AI to speed up clinical trials
Reuters interviews with more than a dozen pharmaceutical company executives, drug regulators, public health experts and AI firms show, however, that the technology is playing a sizeable and growing role in human drug trials.
The Investor (Septmeber 22, 2023) Next & Bio aims to build Asia’s largest library of organoids
“Next & Bio’s top priority is to build an Asian cohort that has organoids cultured from biopsy samples of many individuals in the region,” Next & Bio’s co-CEO Yang Ji-hun said during the interview held at the Seoul headquarters last week. “We are speeding up to make our organoid library ready as soon as possible as organoids are fast emerging as alternatives to animal testing in preclinical research. We aim to become the first mover in the market.”
Phys.Org (September 22, 2023) Machine-learning-boosted drug discovery with 10-fold time reduction
Boosting virtual screening with machine learning allowed for a 10-fold time reduction in the processing of 1.56 billion drug-like molecules. Researchers from the University of Eastern Finland teamed up with industry and supercomputers to carry out one of the world’s largest virtual drug screens.
Genetic Engineering and Biotechnology News (September 22, 2023) CZI to Build Massive GPU Cluster for Decoding Biology with AI
The Chan Zuckerberg Initiative announced that it will build one of the most powerful high-performance computing systems for non-profit life science research in the world and develop machine learning technology and tools to support scientists solving biology’s greatest challenges.
BioSpace (September 21, 2023) Seraxis Announces Closing of Second VC Tranche and Successful Completion of Preclinical Studies of Pancreatic Organoids From Seraxis’ Novel Pancreas-Derived Stem Cells
Leadership team expanded with addition of Chief Corporate Development Officer, Ted Hibben, a 25-year venture-stage business development biotherapeutic industry veteran. Total venture funding tops $50M to date.
Wired (September 20, 2023) The Gruesome Story of How Neuralink’s Monkeys Actually Died
Fresh allegations of potential securities fraud have been leveled at Elon Musk over statements he recently made regarding the deaths of primates used for research at Neuralink, his biotech startup. Letters sent this afternoon to top officials at the US Securities and Exchange Commission (SEC) by a medical ethics group call on the agency to investigate Musk’s claims that monkeys who died during trials at the company were terminally ill and did not die as a result of Neuralink implants. They claim, based on veterinary records, that complications with the implant procedures led to their deaths.
BioTechniques (September 20, 2023) Base editing for more efficient and representative organoids
A collaboration between researchers at the Organoid group at the Hubrecht Institute and the Princess Máxima Center (both Utrecht, The Netherlands), has successfully utilized base editors to integrate a suite of mutations into organoids derived from healthy tissue. Using this approach, the team has created more accurate models of liver, colorectal and endometrial tumors, producing new tools with which to establish novel therapeutics for cancer.
Human Society International (September 20, 2023) Celebrity advocates lobby Congress to pass the Humane Cosmetics Act
A stellar cast assembled on Capitol Hill to support passage of the Humane Cosmetics Act; the Humane Society of the United States, Humane Society Legislative Fund and Humane Society International were joined by celebrity advocates—TV personality and entrepreneur Lala Kent and actress Tricia Helfer—and Lush Cosmetics in urging members of Congress to pass the Humane Cosmetics Act (H.R. 5399), which would end new cosmetics testing on animals in the United States and would prohibit the import and sale of cosmetics in the U.S. that have been newly tested on animals elsewhere in the world.
Med Tech Intelligence (September 20, 2023) The Power of AI to Enhance Clinical Trials
AI not only improves data collection and analysis, it impacts which products are engaged in clinical trials, determines necessary medical criteria, helps design the trials and can even choose the best participating facilities. The result is, organizations that leverage AI will be more successful and will go to market faster than those that don’t.
Physicians Committee (September 20, 2023) 14 Organizations Send Letter Urging Congress to Remove $30 Million in Funding Bill That Would Expand Use of Monkeys in NIH Research
The Physicians Committee for Responsible Medicine and 13 other organizations have sent a letter to Congress, urging them to abandon a “dead-end” strategy to avert a purported shortage of nonhuman primates in research. Rather than allocating $30 million in appropriations to build new research facilities, the group, which includes the Physicians Committee; American Anti-Vivisection Society; Animal Legal Defense Fund; Animal Protection New Mexico; Animal Protection Voters; FOUR PAWS USA; Harvard Law School, Animal Law & Policy Clinic; Humane Society Legislative Fund; Humane Society of the United States; JUSTIFY; National Anti-Vivisection Society; New England Primate Conservancy; People for the Ethical Treatment of Animals; and Rise for Animals, would like Congress to encourage the National Institutes of Health (NIH) to shift to human-relevant research methods, which the group says have the greatest potential for understanding, improving, and protecting human health.
Medical Express (September 19, 2023) ‘Bioprinting’ living brain cell networks in the lab
Monash University Engineering researchers have successfully used “bioinks” containing living nerve cells (neurons) to print 3D nerve networks that can grow in the laboratory and transmit and respond to nerve signals. The technology has been published in Advanced Healthcare Materials.
GenomeWeb UPDATE: (September 19, 2023) Bipolar Disorder Research Funding Organization Awards $18M in Grants to NYGC, Others
Washington, DC-based BD², a collaboration between three family philanthropies and the Milken Institute, said that it awarded grants of up to $4.5 million over three years to separate teams led by investigators at the New York Genome Center (NYGC), the Wyss Institute at Harvard University, Stanford University, and Yale University. The awards are being made through the BD² “Discovery Research” program.
Drug Target Review (September 19, 2023) Advanced 3D cell-based technologies
Recent regulatory changes in the US and Europe are driving the adoption of advanced 3D cell-based technologies, such as organoids and organ-on-chips, in drug development, replacing traditional animal testing and offering safer, cost-effective alternatives.
Phys.Org (September 18, 2023) A modern digital light processing technology to 3D print microfluidic chips
Materials scientists have introduced digital light processing as a cost-effective microfabrication approach to 3D print microfluidic chips, although the fabrication resolution of these microchannels are limited to a scale of sub-100 microns.
BioSpace (September 18, 2023) Curi Bio Launches Nautilus™ and Stingray™ Platforms for Advancing Translational Research
With Nautilus, researchers can now interrogate the electrophysiology of their 2D or 3D cell cultures using the latest optical measurement techniques at the push of a button. The Stingray platform allows for maturation of 3D tissues via electrical stimulation with a level of versatility currently unmatched in the industry.
-
- You must be logged in to reply to this topic.